Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Medical Research Council
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Information provided by (Responsible Party):
PENTA Foundation
ClinicalTrials.gov Identifier:
NCT01641016
First received: July 12, 2012
Last updated: July 16, 2013
Last verified: July 2013

July 12, 2012
July 16, 2013
April 2011
June 2014   (final data collection date for primary outcome measure)
HIV-1 RNA ≥50 copies/ml (confirmed on a separate sample within 1 week) at any of week 4, 12, 24, 36 or 48. [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
This outcome measure only considers HIV-1 RNA measurements at these time points due to the difference in viral load monitoring in the pilot phase and the main trial. However if a young person enrolled in the pilot phase has HIV-1 RNA ≥50 copies/ml at weeks 1, 2 or 3 (reproducible on the same sample) or at week 8 (confirmed on the same sample within 1 week), they will be considered as reaching the primary outcome at week 4 and 12 respectively
Same as current
Complete list of historical versions of study NCT01641016 on ClinicalTrials.gov Archive Site
  • HIV-1 RNA <50 c/ml at 24 and 48 weeks [ Time Frame: 24 and 48 weeks ] [ Designated as safety issue: No ]
  • Number of HIV mutations present at week 4, 12, 24, 36 or 48 conferring resistance to drugs taken at randomisation or during the tria [ Time Frame: Weeks 4, 12, 24, 36, 48 ] [ Designated as safety issue: No ]
  • Change in CD4 (absolute and percentage) from randomisation to 24 and 48 weeks [ Time Frame: 24 and 48 weeks ] [ Designated as safety issue: No ]
  • Change in ART (defined as any change from the ART regimen at randomisation) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Grade 3 or 4 clinical and laboratory adverse events [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
  • ART treatment modifying adverse events (all grades) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • New CDC stage B or C diagnosis or death [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Changes in fasting glucose, cholesterol, triglycerides, LDL, HDL and VLDL levels through 48 weeks [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Adherence, acceptability, and quality of life over 48 weeks as assessed by patient completed questionnaires [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection
BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection

The overall aim of the BREATHER trial is to evaluate the role of Short-Cycle Therapy (SCT) in the management of HIV-infected young people who have responded well to antiretroviral therapy (ART) and to determine whether young people with chronic HIV infection undergoing Short-Cycle Therapy of five days on ART and two days off maintain the same level of viral load suppression as those on continuous therapy, over 48 weeks.

To assess the advantages and disadvantages of the strategy, the incidence of toxicities, immunological control, resistance mutations, acceptability, quality of life and adherence to the randomised strategy will also be compared.

Importantly, because of insufficient data on short-term viral load rebound after stopping ART in this population, the trial will incorporate an initial pilot phase in selected centres, to assess the safety of the SCT strategy by evaluating detailed HIV-1 RNA profiles of participants on the SCT strategy.

Not Provided
Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV
Drug: efavirenz
May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
Other Name: Trade name: Sustiva
  • Active Comparator: Continuous Therapy
    Continue with current antiretroviral therapy regime as per standard care
    Intervention: Drug: efavirenz
  • Experimental: Short Cycle Therapy
    Take current antiretroviral therapy 5 days a week (2 days off) as instructed by clinician
    Intervention: Drug: efavirenz
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
160
June 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-1 infected young people aged 8 to 24 years inclusive (Young people recruited between the ages of 16-21 must either be in regular physical contact with their clinician or be able to transfer to an adult physician at the same site for follow-up or to an affiliated adult site).
  • Parents/carers and/or young people, where applicable, willing to provide informed consent.
  • On a stable first-line ART treatment containing at least 2 NRTIs/NtRTIs and EFV for at least 12 months and willing to continue the regimen throughout the study period. Young people on regimens containing nevirapine (NVP) or a boosted protease inhibitor with undetectable viral load for over one year who wish to enrol should switch to EFV. Once they are stable on the EFV containing regimen for more than 12 weeks they may be enrolled (must have 2 subsequent HIV-1 RNA measurements <50 c/ml over a minimum period of 12 weeks). Previous dual therapy and/or substitution of NRTIs is allowed providing any changes were not for disease progression, immunological or virological failure (where virological failure is defined as two successive HIV-1 RNA results>1000 c/ml) subsequent to virological control having been achieved on ART.
  • Viral suppression (HIV-1 RNA <50 c/ml) for at least the prior 12 months (at least the last 3 measurements, including screening): young people who have experienced a single viral load >50 but <1000 copies/ml (preceded and followed by VL<50 c/ml) in the last 12 months can be enrolled.
  • CD4 cell count ≥350 106/L at screening visit.
  • Centre must routinely use an assay which detects HIV RNA-1 viral load ≥50 c/ml.

Exclusion Criteria:

  • Pregnancy or risk of pregnancy in females of child bearing potential.
  • Acute illness (young people may be enrolled after illness).
  • Receiving concomitant therapy for an acute illness (young people may be enrolled after finishing therapy).
  • A creatinine, AST or ALT of grade 3 or above at screening.
  • On a regimen including nevirapine or a boosted PI (young people may switch to an EFV based regimen).
  • Previous ART monotherapy (except for the prevention of mother-to-child transmission)
Both
8 Years to 24 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   France,   Germany,   Ireland,   Thailand,   Uganda,   Ukraine,   United Kingdom
 
NCT01641016
BREATHER (PENTA 16), 2009-012947-40
Yes
PENTA Foundation
PENTA Foundation
  • Medical Research Council
  • French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Principal Investigator: Karina M Butler, MRCPI Medical Research Council
PENTA Foundation
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP